FDA Recalls AVASTIN Syringes Due to Sterility Assurance Concerns
Oregon Compounding Centers is recalling AVASTIN syringes because quality control issues observed during an FDA inspection present a potential risk to sterility assurance.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or high-risk conditions like sterility assurance failures in injectable drugs are categorized as Severe.
Plain-English summary
Oregon Compounding Centers, Inc. dba Creative Compounds is recalling 5,483 syringes of AVASTIN, 1.25mg/0.5mL, injectable. The product is distributed in Oregon and Washington.
The recall is due to a lack of sterility assurance. The FDA identified concerns associated with quality control procedures during a recent inspection that present a potential risk to the sterility of the compounded products. The recall includes all lots of sterile products compounded by the pharmacy that are not expired.
Consumers and healthcare providers should check their inventory for the specific lot numbers listed in the recall notice and discontinue use of the affected products.
The recalled product
- Product
- AVASTIN, 1.25mg/0.5mL, injectable, 0.05 mL plastic syringe, RX, Creative Compounds, Wilsonville, OR 97070.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: 20140715@13
- discard date: 11/3/2014
- Lot #: 20140716@25
- discard date: 10/14/2014
- Lot #: 20140717@7
- discard date: 10/15/2014
- Lot #: 20140724@14
- discard date: 10/22/2014
- Lot #: 20140724@15
- Lot #: 20140729@11
- discard date: 10/27/2014
- Lot #: 20140801@17
- discard date: 10/30/2014
- Lot #: 20140805@1
- Lot #: 20140807@13
- discard date: 11/5/2014
- Lot #: 20140811@30
- discard date: 11/9/2014
- Lot #: 20140813@10
- discard date: 11/11/2014
Distribution
Part of a larger recall action
This product is one of 56 recalled by Oregon Compounding Centers, Inc. dba Creative Compounds under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Oregon Compounding Centers, Inc. dba Creative Compounds
See all →- SevereGanciclovir Syringes Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Papaverine Injectable Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Injectable Methycobalamin Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereCreative Compounds Recalls Ceftazidime Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Vitamin B Complex Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
Same hazard · sterility assurance
See all →- HighArrowhead DE LLC Recalls Arrow-LOK Implants Due to Sterility Assurance Concerns
FDA (Devices) · 2026-08-26
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereChloraPrep One-Step Applicators Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2026-07-08
- SevereArrow access trays and PSI kits contain recalled supplier drugs
FDA (Devices) · 2026-06-24